P53 Mutations Change Phosphatidylinositol Acyl Chain Composition-Reference-Cited by-同舟云学术

P53 Mutations Change Phosphatidylinositol Acyl Chain Composition

Published:2015-01 Issue:1 Volume:10 Page:8-19
ISSN:2211-1247
Container-title:Cell Reports
language:en
Short-container-title:Cell Reports

Author:

Naguib Adam,Bencze Gyula,Engle Dannielle D.,Chio Iok I.C.,Herzka Tali,Watrud Kaitlin,Bencze Szilvia,Tuveson David A.,Pappin Darryl J.,Trotman Lloyd C.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference38 articles.

1. Reassessment of K-ras mutations at codon 12 by direct PCR and sequencing from tissue microdissection in human pancreatic adenocarcinomas;Aoki;Pancreas,2000

2. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure;Aoyagi;Curr. Pharm. Des.,2011

3. Intraoperative tissue identification using rapid evaporative ionization mass spectrometry;Balog;Sci. Transl. Med.,2013

4. Comparative analysis of mutations in the p53 and K-ras genes in pancreatic cancer;Berrozpe;Int. J. Cancer,1994

5. Curvature, lipid packing, and electrostatics of membrane organelles: defining cellular territories in determining specificity;Bigay;Dev. Cell,2012

Cited by 56 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Differentiating human phospholipase A2's activity toward phosphatidylinositol, phosphatidylinositol phosphate and phosphatidylinositol bisphosphate;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2024-10

2. The LCLAT1/LYCAT acyltransferase is required for EGF-mediated phosphatidylinositol-3,4,5-trisphosphate generation and Akt signaling;Molecular Biology of the Cell;2024-09-01

3. Phosphoinositide and redox dysregulation by the anticancer methylthioadenosine phosphorylase transition state inhibitor;Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids;2023-09

4. Phosphoinositide acyl chain saturation drives CD8+ effector T cell signaling and function;Nature Immunology;2023-02-02

5. Targeting Class I-II-III PI3Ks in Cancer Therapy: Recent Advances in Tumor Biology and Preclinical Research;Cancers;2023-01-27